Skip to main content
Equibles
SGHT logo

SGHT · Sight Sciences, Inc.

Track SGHT — free

Use SGHT with AI

Ask our own analyst here, or connect this data to the AI you already use.

Ask ALVIS about SGHT

Free, nothing to set up — ALVIS runs on the same tools and cites every figure.

or use your own AI

The free Equibles MCP server lets any client query SEC filings, earnings calls, KPIs, holdings and prices directly — read-only, OAuth-secured, cited to the filing.

ChatGPT Claude Gemini
Server URL
https://mcp.equibles.com/mcp
All connection guides →
$8.14 -0.18 (-2.16%) At close · Aug 14
Market Cap
$448.42M
Shares
55.09M

Sight Sciences, Inc. Earnings Call Transcripts

Every quarterly earnings call for Sight Sciences, Inc. (SGHT) — the full transcript with speaker labels, the audio replay, AI call highlights and a management-tone score, plus the matching 8-K earnings release and the quarter's 10-Q or 10-K. Investor days and conferences appear here too.

Revenue & result across quarters

Revenue Net income YoY up YoY down artefacts
▲42.6% $18.68M −$22.23M '22 Q3 22-11-10 ▲39.9% $20.54M −$16.91M '22 Q4 23-01-09 ▲26.5% $18.82M −$17.07M '23 Q1 23-05-04 ▲36.2% $23.47M −$14.75M '23 Q2 23-08-03 ▲7.1% $20.01M −$13.04M '23 Q3 23-11-07 ▼8.7% $18.75M −$10.69M '23 Q4 24-03-07 ▲2.3% $19.27M −$16.27M '24 Q1 24-03-31 ▼9% $21.37M −$12.33M '24 Q2 24-08-01 ▲0.7% $20.16M −$11.07M '24 Q3 24-11-07 ▲1.7% $19.07M −$11.85M '24 Q4 25-01-14 ▼9.1% $17.51M −$14.15M '25 Q1 25-05-08 ▼8.5% $19.56M −$11.94M '25 Q2 25-08-07 ▼1.2% $19.91M −$8.17M '25 Q3 25-11-06 ▲6.9% $20.39M −$4.16M '25 Q4 26-03-04 ▲12.5% $19.70M −$12.98M '26 Q1 26-05-06 LATEST ▲19.5% $23.39M −$4.45M '26 Q2 26-08-05
Earnings call
FY26 · Q2
2026-08-05
Sight Sciences Second Quarter 2026 Earnings Results
Confident tone Interventional Glaucoma / Omni platform Payer coverage and market access expansion Path to profitability / cash flow discipline
Revenue
$23.39M
▲ 19.5% YoY
Diluted EPS
$-0.08
Gross margin
91.4%
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY26 · Q1
2026-05-06
Sight Sciences, Inc. Q1 FY2026 Earnings Call
Confident tone Interventional Glaucoma (Omni) Growth Market Access Expansion (MACs and Commercial Payers) Intersection of Intervention (Cross-Selling Synergies)
Revenue
$19.70M
▲ 12.5% YoY
Diluted EPS
$-0.24
Gross margin
86.2%
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY25 · Q4
2026-03-04
Sight Sciences, Inc. Q4 FY2025 Earnings Call
Positive tone 2026 financial guidance and growth outlook Interventional Dry Eye / TearCare commercialization MAC reimbursement expansion
Revenue
$20.39M*
▲ 6.9% YoY
Gross margin
87.3%
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-K
Earnings call
FY25 · Q3
2025-11-06
Sight Sciences, Inc. Q3 FY2025 Earnings Call
Confident tone TearCare reimbursement and MAC coverage Surgical Glaucoma / OMNI growth 2025 guidance raise
Revenue
$19.91M
▼ 1.2% YoY
Diluted EPS
$-0.16
Gross margin
86.4%
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY25 · Q2
2025-08-07
Sight Sciences, Inc. Q2 FY2025 Earnings Call
Revenue
$19.56M
▼ 8.5% YoY
Diluted EPS
$-0.23
Gross margin
84.8%
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY25 · Q1
2025-05-08
Sight Sciences, Inc. Q1 FY2025 Earnings Call
Positive tone Omni surgical glaucoma performance TearCare reimbursement progress Dry eye segment growth
Revenue
$17.51M
▼ 9.1% YoY
Diluted EPS
$-0.28
Gross margin
86.2%
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY24 · Q4
2025-01-14
Sight Sciences, Inc. Q4 FY2024 Earnings Call
Cautious tone Surgical Glaucoma (OMNI) Performance and Strategy TearCare Reimbursement and Dry Eye Progress MIGS Market Headwinds and LCD Restrictions
Revenue
$19.07M*
▲ 1.7% YoY
Gross margin
86.8%
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-K
Earnings call
FY24 · Q3
2024-11-07
Sight Sciences, Inc. Q3 FY2024 Earnings Call
Cautious tone Surgical Glaucoma / MIGS Market Recovery TearCare / Dry Eye Franchise and Payer Access OMNI Product and Clinical Profile
Revenue
$20.16M
▲ 0.7% YoY
Diluted EPS
$-0.22
Gross margin
83.9%
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY24 · Q2
2024-08-01
Sight Sciences, Inc. Q2 FY2024 Earnings Call
Confident tone Dry Eye / TearCare Commercialization and Coverage SAHARA Clinical Data and Health Economics TearCare Price Increase and Adoption
Revenue
$21.37M
▼ 9% YoY
Diluted EPS
$-0.25
Gross margin
85.8%
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY24 · Q1
2024-03-31
Sight Sciences, Inc. Q1 FY2024 Earnings Call
Positive tone Surgical Glaucoma growth and recovery Dry Eye / TearCare business Sales force and commercial scaling
Revenue
$19.27M
▲ 2.3% YoY
Diluted EPS
$-0.33
Gross margin
85.5%
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY23 · Q4
2024-03-07
Sight Sciences, Inc. Q4 FY2023 Earnings Call
Positive tone Surgical Glaucoma / OMNI Performance LCD Reimbursement Uncertainty 2024 Guidance & Growth Outlook
Revenue
$18.75M*
▼ 8.7% YoY
Gross margin
85.2%
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-K
Earnings call
FY23 · Q3
2023-11-07
Sight Sciences, Inc. Q3 FY2023 Earnings Call
Revenue
$20.01M
▲ 7.1% YoY
Diluted EPS
$-0.27
Gross margin
86.6%
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY23 · Q2
2023-08-03
Sight Sciences, Inc. Q2 FY2023 Earnings Call
Revenue
$23.47M
▲ 36.2% YoY
Diluted EPS
$-0.30
Gross margin
85.6%
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY23 · Q1
2023-05-04
Sight Sciences, Inc. Q1 FY2023 Earnings Call
Revenue
$18.82M
▲ 26.5% YoY
Diluted EPS
$-0.35
Gross margin
83.8%
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY22 · Q4
2023-01-09
Sight Sciences, Inc. Q4 FY2022 Earnings Call
Revenue
$20.54M*
▲ 39.9% YoY
Gross margin
82.2%
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-K
Earnings call
FY22 · Q3
2022-11-10
Sight Sciences, Inc. Q3 FY2022 Earnings Call
Revenue
$18.68M
▲ 42.6% YoY
Diluted EPS
$-0.46
Gross margin
84.3%
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY22 · Q2
2022-08-11
Sight Sciences, Inc. Q2 FY2022 Earnings Call
Revenue
$17.23M
▲ 37.4% YoY
Diluted EPS
$-0.50
Gross margin
84.1%
Rev · 7q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY22 · Q1
2022-05-10
Sight Sciences, Inc. Q1 FY2022 Earnings Call
Revenue
$14.88M
▲ 72.3% YoY
Diluted EPS
$-0.49
Gross margin
79.6%
Rev · 6q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY21 · Q4
2022-03-24
Sight Sciences, Inc. Q4 FY2021 Earnings Call
Revenue
$14.69M*
Gross margin
86.8%
Rev · 5q Trailing quarterly revenue
Audio Transcript Slides 8-K10-K
Earnings call
FY21 · Q3
2021-11-10
Sight Sciences, Inc. Q3 FY2021 Earnings Call
Revenue
$13.10M
▲ 51.4% YoY
Diluted EPS
$-0.43
Gross margin
84.3%
Rev · 5q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY21 · Q2
2021-08-12
Sight Sciences, Inc. Q2 FY2021 Earnings Call
Revenue
$12.54M
▲ 257.9% YoY
Gross margin
81.6%
Rev · 4q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Showing 1–21 of 21 earnings calls
Key facts CIK 1531177 CUSIP 82657M105 13F (30d) 108 filings 108 filers Visit website Investor relations

Report a Problem

Category
Description
Email (optional, for follow-up)